Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • EMA suspends sale of...

    EMA suspends sale of GE's MRI Contrast, GE asks agency to reconsider

    Written by supriya kashyap kashyap Published On 2017-03-17T11:50:28+05:30  |  Updated On 17 March 2017 11:50 AM IST
    EMA suspends sale of GEs MRI Contrast, GE asks agency to reconsider

    General Electric Co's healthcare business said it had requested the European Medicines Agency to reconsider the recommendation made by its panel to suspend the marketing authorization of certain agents used in MRI scanning.


    The recommendation by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) last week came after a small amount of chemical deposit was found in the brains of patients. No harm linked to gadolinium in the brain has been reported.


    The panel recommended the ban of GE Healthcare's MRI contrast agent called omniscan, which is sold globally.


    The committee suggested the EMA to stop the marketing of four linear gadolinium contrast agents (GdCAs), which are chemical substances injected into the body to improve the quality of the MRI images.


    GE Healthcare said it would employ all available measures and continue its research program to understand any potential risks from brain gadolinium.


    "GE Healthcare remains firm in our evidence-based belief that the overall benefit-risk profile of linear agents including Omniscan is positive," the company said on Thursday.

    European Medicines AgencyGE HealthGeneral ElectricMRI contrastMRI drugomniscanPharmacovigilance Risk Assessment CommitteePRAC
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok